Disclosures: Stephen Congly: Axcella Health, Inc.: Grant/Research Support, AstraZenica: Grant/Research Support, Merck: Grant/Research Support, Ipsen: Grant/Research Support, Bausch Health: Grant/Research Support, Gilead Sciences Canada: Grant/Research Support, Gilead Sciences Canada: Grant/Research Support, AstraZeneca: Consultant, GSK: Consultant, Mayur Brahmania: Nothing to Disclose, Conar O'Neil: Gilead Sciences: Speaking and Teaching, Gilead Sciences: Advisor, AbbVie: Speaking and Teaching, ViiV: Advisor, ViiV: Speaking and Teaching, Karen Doucette: Roche: Grant/Research Support, GSK: Grant/Research Support, Altimmune: Grant/Research Support, Mang Ma: Nothing to Disclose, Carla Coffin: Gilead Sciences: Grant/Research Support, Janssen Pharmaceuticals: Grant/Research Support, GSK: Speaking and Teaching, Altimmune Pharmacueticals: Fund paid to the University of Calgary, Riche Pharmaceuticals: Grant/Research Support, GSK: Funds paid to the University of Calgary 1709 VARIATION IN NULEOS(T)IDE ANALOGUE USE IN MEDICARE PART D THROUGHOUT THE UNITED STATES Stephen Congly 1 Conar O'Neil 2 Karen Doucette 2 Mang Ma 2 Mayur Brahmania 1 Carla Coffin 1 , 1 University of Calgary, 2 University of Alberta Background: Treatment for chronic hepatitis B (CHB) with nucleos(t)ide analogues (NA) suppresses viral replication and prevents progression to fibrosis and liver cancer
On the other hand, capsules and nasal sprays will have to travel to your GIT for absorption
Under glucose deprivation, tumor cells rely on an alternative energy-generating pathway such as glutaminolysis [25,67] [Figure 1D]
10.1016/j.nutres.2013.08.009 297
Christie, E
